Brief: X4 Pharmaceuticals - Believes It Has Sufficient Funds To Support Company Operations Into 2025

X4 Pharmaceuticals

09/11/2023 11:27

Nov 9 (Reuters) - X4 Pharmaceuticals Inc  XFOR.O :
    * X4 PHARMACEUTICALS INC - X4 BELIEVES IT HAS SUFFICIENT
FUNDS TO
SUPPORT COMPANY OPERATIONS INTO 2025
    * X4 PHARMACEUTICALS INC - X4 HAD $142.7 MILLION IN CASH,
CASH
EQUIVALENTS, RESTRICTED CASH, AND MARKETABLE SECURITIES AS OF
SEPTEMBER 30, 2023
    * X4 PHARMACEUTICALS INC - PIVOTAL, GLOBAL PHASE 3 TRIAL OF
MAVORIXAFOR IN CHRONIC NEUTROPENIA EXPECTED TO INITIATE IN 1H
2024
    * X4 PHARMACEUTICALS - U.S. NDA FOR MAVORIXAFOR IN WHIM
SYNDROME
ACCEPTED FOR PRIORITY REVIEW, ESTABLISHING A PDUFA TARGET ACTION
DATE OF APRIL 30, 2024

Source text for Eikon:  ID:nGNX5GWnBP 
Further company coverage:  XFOR.O 

 ((Reuters.Briefs@thomsonreuters.com;))